Literature DB >> 6345019

Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer.

M L Slevin, V J Harvey, P F Wrigley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6345019     DOI： 10.1007/bf00255772

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  4 in total

1.  Adjuvant chemotherapy of large bowel cancer.

Authors:  J M Gilbert
Journal:  Cancer Treat Rev       Date:  1982-09       Impact factor: 12.111

2.  The survival of patients with colorectal cancer treated in a regional hospital.

Authors:  P G Gill; P J Morris
Journal:  Br J Surg       Date:  1978-01       Impact factor: 6.939

3.  Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.

Authors:  J M Gilbert; K Hellmann; M Evans; P G Cassell; B Stoodley; H Ellis; C Wastell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.